共查询到20条相似文献,搜索用时 0 毫秒
1.
2.
Srokowski TP Liebmann JE Modiano MR Cohen GI Pro B Romaguera JE Kuepfer C Singer JW Fayad LE 《Cancer》2011,117(22):5067-5073
BACKGROUND:
Pixantrone dimaleate (pixantrone) has been shown to have antitumor activity in leukemia and lymphoma in vitro models and to lack delayed cardiotoxicity associated with mitoxantrone in animal models. FND‐R, a combination regimen of fludarabine, mitoxantrone, dexamethasone, and rituximab, has been shown to be an effective regimen for low‐grade lymphomas.METHODS:
This dose‐escalation study, with an expansion cohort, was conducted to evaluate the safety and preliminary efficacy of FPD‐R, in which pixantrone was substituted for mitoxantrone in the FND‐R regimen, in patients with relapsed or refractory indolent non‐Hodgkin lymphoma (NHL). Escalated doses of pixantrone were administered to newly enrolled patients on day 2 of each 28‐day cycle of FPD‐R.RESULTS:
Twenty‐eight of 29 enrolled patients received at least 1 cycle of FPD‐R (median, 5 cycles). Pixantrone 120 mg/m2 was identified as the recommended dose in this regimen. Grade 3‐4 adverse events were primarily hematologic; grade 3‐4 lymphopenia occurred in 89% of patients and leukopenia in 79%. No patients developed congestive heart failure or grade 3‐4 cardiac adverse events. Left ventricular ejection fraction decreases occurred in 8 (29%) patients, and most were grade 1 or 2, transient, and asymptomatic. The overall response rate was 89%. Estimated survival was 96% after 1 year and 92% after 3 years.CONCLUSIONS:
The FPD‐R regimen was well‐tolerated and highly active in patients with relapsed or refractory indolent NHL. Cancer 2011;. © 2011 American Cancer Society. 相似文献3.
Brad S. Kahl MD Nancy L. Bartlett MD John P. Leonard MD Ling Chen PhD Kristen Ganjoo MD Michael E. Williams MD Myron S. Czuczman MD K. Sue Robinson MD Robin Joyce MD Richard H. van der Jagt MD Bruce D. Cheson MD 《Cancer》2010,116(1):106-114
BACKGROUND:
Bendamustine hydrochloride is a novel alkylating agent. In this multicenter study, the authors evaluated the efficacy and toxicity of single‐agent bendamustine in patients with rituximab‐refractory, indolent B‐cell lymphoma.METHODS:
Eligible patients (N = 100, ages 31‐84 years) received bendamustine at a dose of 120 mg/m2 by intravenous infusion on Days 1 and 2 every 21 days for 6 to 8 cycles. Histologies included follicular (62%), small lymphocytic (21%), and marginal zone (16%) lymphomas. Patients had received a median of 2 previous regimens (range, 0‐6 previous regimens), and 36%were refractory to their most recent chemotherapy regimen. Primary endpoints included overall response rate (ORR) and duration of response (DOR). Secondary endpoints were safety and progression‐free survival (PFS).RESULTS:
An ORR of 75% (a 14% complete response rate, a 3% unconfirmed complete response rate, and a 58% partial response rate) was observed. The median DOR was 9.2 months, and median PFS was 9.3 months. Six deaths were considered to be possibly treatment related. Grade 3 or 4 (determined using National Cancer Institute Common Toxicity Criteria [version 3.0.19]. reversible hematologic toxicities included neutropenia (61%), thrombocytopenia (25%), and anemia (10%). The most frequent nonhematologic adverse events (any grade) included nausea (77%), infection (69%), fatigue (64%), diarrhea (42%), vomiting (40%), pyrexia (36%), constipation (31%), and anorexia (24%).CONCLUSIONS:
Single‐agent bendamustine produced a high rate of objective responses with acceptable toxicity in patients with recurrent, rituximab‐refractory indolent B‐cell lymphoma. Cancer 2010. © 2010 American Cancer Society. 相似文献4.
Maria K. Angelopoulou Theodoros P. Vassilakopoulos Ioannis Batsis Ioanna Sakellari Konstantinos Gkirkas Vasiliki Pappa Panagiota Giannoulia Ioannis Apostolidis Christos Apostolopoulos Paraskevi Roussou Panayiotis Panayiotidis Maria Dimou Marie‐Christine Kyrtsonis Maria Palassopoulou Georgios Vassilopoulos Maria Moschogiannis Christina Kalpadakis Dimitrios Margaritis Alexander Spyridonidis Eurydiki Michalis Konstantinos Anargyrou Panagiotis Repousis Eleutheria Hatzimichael Zoi Bousiou Elias Poulakidas Dimitrios Grentzelias Nikolaos Harhalakis Gerassimos A. Pangalis Achilles Anagnostopoulos Panagiotis Tsirigotis 《Hematological oncology》2018,36(1):174-181
This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety‐five patients with R/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% were males. Sixty‐seven patients received BV after autologous stem cell transplantation failure, whereas 28 patients were treated with BV without a prior autologous stem cell transplantation, due to advanced age/comorbidities or chemorefractory disease. The median number of prior treatments was 4 and 44% of the patients were refractory to their most recent therapy. The median number of BV cycles was 8 (range, 2‐16), and the median time to best response was the fourth cycle. Fifty‐seven patients achieved an objective response: twenty‐two (23%), a complete response (CR), and 35 patients (37%), a partial, for an overall response rate of 60%. Twelve patients (13%) had stable disease, and the remaining twenty‐six (27%) had progressive disease as their best response. At a median follow‐up of 11.5 months, median progression‐free survival and overall survival were 8 and 26.5 months, respectively. Multivariate analysis showed that chemosensitivity to treatment administered before BV was associated with a significantly increased probability of achieving response to BV (P = .005). Bulky disease (P = .01) and response to BV (P <.001) were significant for progression‐free survival, while refractoriness to most recent treatment (P = .04), bulky disease (P = .005), and B‐symptoms (P = .001) were unfavorable factors for overall survival. Among the 22 CRs, 5 remain in CR with no further treatment after BV at a median follow‐up of 13 months. In conclusion, our data indicate that BV is an effective treatment for R/R HL patients even outside clinical trials. Whether BV can cure a fraction of patients remains to be seen. 相似文献
5.
Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation 总被引:5,自引:0,他引:5
C. Girouard J. Dufresne K. Imrie A. K. Stewart J. Brandwein H. M. Prince D. Pantolony A. Keating M. Crump 《Annals of oncology》1997,8(7):675-680
Background: The role of intensive chemotherapy with autologous blood andmarrow transplantation (ABMT) for patients with relapsed or refractoryintermediate grade non-Hodgkins lymphoma has recently been established.However, conventional dose salvage chemotherapy is frequently used todetermine chemotherapy sensitivity and reduce tumor bulk prior to intensivetherapy. Different salvage regimens have been proposed but none appearssignificantly superior. The purpose of this study was to determine theefficacy of mini-BEAM salvage chemotherapy in patients referred for ABMT andto define prognostic factors of response.Patients and methods: One hundred four patients referred forconsideration of ABMT after failure of primary anthracycline-basedchemotherapy received BCNU 60 mg/m2 day 1, etoposide 75mg/m2 day 2–5, ara-C 100 mg/m2 q12h day2–5, melphalan 30 mg/m2 day 6 (mini-BEAM) until maximumtumor reduction. Median age was 52 (range 18–65); 57% had failedto achieve a complete response (CR) to doxorubicin-based chemotherapy atdiagnosis and only 13% had a previous CR lasting > 12 months.Seventy-six received mini-BEAM as first salvage chemotherapy.Results: The overall response rate (RR) was 37% (95%confidence interval (CI) 28–46%) with 12 patients achieving CRand 25 achieving PR. Theresponse rate among patients treated as first salvage was 43% comparedto 20% for patients who had failed to respond to a previous salvageregimen. Only 15% of patients who failed to respond to mini-BEAMresponded to another conventional dose salvage regimen. Thirty-eight of 104patients ultimately demonstrated sufficient response to proceed to ABMT.Actuarial survival at four years is 22% for all 104 patients, and36% for those who went on to ABMT. For those who were not transplanted,four-year survival was 18%. B symptoms and tumor burden at relapse weresignificant predictors of response to mini-BEAM in multivariate analysis, andidentified a poor prognosis group of patients unlikely to be cured by thisapproach.Conclusions: Mini-BEAM does not appear to be a superior salvage regimen inthis high-risk group of relapsed or refractory NHL patients for whom ABMT wasthe ultimate treatment intention. Only one-third of patients referred for ABMTultimately proceed to transplant; alternative treatment strategies should bedeveloped for those with a low likelihood of cure by this approach. 相似文献
6.
Musolino A Boggiani D Panebianco M Vasini G Salvagni S Franciosi V Ardizzoni A 《Cancer》2011,117(5):964-973
BACKGROUND: This study was designed to assess the activity and safety of dose‐adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab (DA‐POCH‐R) in elderly patients with poor‐prognostic untreated diffuse large B‐cell non‐Hodgkin lymphoma (DLBCL). METHODS: From April 2006 to November 2009, 23 patients, aged ≥70 years, with an age‐adjusted International Prognostic Index (IPI) of 2 or 3, were enrolled. Only patients with left ventricular ejection fraction (LVEF) ≥50% were allowed. The DA‐POCH‐R regimen was administered every 3 weeks for a minimum of 6 and a maximum of 8 cycles. RESULTS: Median patient age was 77 years (range, 70‐90 years); 83% of patients had Ann Arbor stage III to IV disease. Median LVEF at baseline was 62%. Four (17%) patients had a history of abnormal cardiovascular conditions. Twenty‐one (91%) patients were evaluable for response. The overall response rate was 90%, with a complete response rate of 57%. The 3‐year overall survival and event‐free survival rates were 56% and 54%, respectively. Neutropenia (48%) was the most frequent grade 3 to 4 adverse event (AE); no grade 3 to 4 cardiac AEs were observed. CONCLUSIONS: DA‐POCH‐R was an active and safe combination therapy for patients aged ≥70 years with poor‐prognostic untreated DLBCL. This regimen was a reasonable alternative for elderly patients who were not considered to tolerate standard R‐CHOP treatment. Cancer 2011. © 2010 American Cancer Society. 相似文献
7.
Andrew M. Evens DO MSc Ann Vanderplas MS Ann S. LaCasce MD Allison L. Crosby MS Auayporn P. Nademanee MD Mark S. Kaminski MD Gregory A. Abel MD MPH Michael Millenson MD Myron S. Czuczman MD Maria A. Rodriguez MD Joyce Niland PhD Andrew D. Zelenetz MD PhD Leo I. Gordon MD Jonathan W. Friedberg MD MSc 《Cancer》2013,119(20):3662-3671
8.
Jane E. Churpek MD Barbara Pro MD Koen van Besien MD Justin Kline MD Kathy Conner RN James L. Wade III MD Fredrick Hagemeister MD Theodore Karrison PhD Sonali M. Smith MD 《Cancer》2013,119(9):1683-1689
BACKGROUND:
The management of relapsed aggressive lymphomas remains problematic. Ixabepilone (BMS‐247550, epothilone B analog), a potent inhibitor of tubulin disassembly, has promising preclinical and early‐phase clinical activity in drug‐resistant malignancies.METHODS:
This multicenter phase 2 clinical trial tested the activity and safety of ixabepilone in relapsed/refractory aggressive lymphoma patients with either chemosensitive (at least a partial response [PR] to most recent chemotherapy) or chemoresistant (less than PR to most recent chemotherapy) disease at 20 mg/m2 given intravenously weekly on days 1, 8, and 15 of a 28‐day cycle.RESULTS:
Fifty‐one enrolled patients with a median age of 66 years received at least 1 dose of ixabepilone. Diffuse large B‐cell lymphoma (n = 25; 49%), mantle cell lymphoma (n = 16; 31%), and transformed follicular lymphoma (n = 5; 10%) were the most frequent histologies. Patients were heavily pretreated, with more than one‐quarter having received 4 or more prior therapies. The overall response rate was 27% (14 of 51 patients) with 12% (6 patients) experiencing complete responses and 16% (8 patients) with PRs. All responses were in patients with chemosensitive disease. The median time to response was 2 cycles with a median duration of response of 9.7 months.CONCLUSIONS:
Ixabepilone was well‐tolerated, with neutropenia, peripheral sensory neuropathy, fatigue, and nausea as the major toxicities. Ixabepilone has modest single‐agent activity in patients with recurrent chemosensitive aggressive lymphomas. Cancer 2013. © 2013 American Cancer Society. 相似文献9.
Thomas S. Y. Chan Yu-Yan Hwang Pek-Lan Khong Anskar Y. H. Leung Chor-Sang Chim Eric W. C. Tse Yok-Lam Kwong 《Hematological oncology》2020,38(5):726-736
The efficacy and safety of low-dose anti-PD1 antibodies in relapsed/refractory classical Hodgkin lymphoma (cHL) require confirmation. Pembrolizumab (100 mg every 3 weeks, Q3W) or nivolumab (40 mg Q2W) were administered to patients with relapsed/refractory cHL. In the pembrolizumab cohort (N = 11), who had failed a median of three (1–6) therapies (brentuximab vedotin [BV]: 91%; autologous hematopoietic stem cell transplantation [auto-HSCT]: 18%), the overall response rate (ORR) by positron emission tomography–computed tomography was 100% (metabolic complete response [mCR]: 73%; partial response [PR]: 27%). Median cumulative dose for achieving best response was 400 (300–800) mg. Median progression-free survival (PFS) was 35 months. Median overall survival (OS) was not reached. Adverse events (AEs) of grade 1–2 were observed in three patients. In the nivolumab cohort (N = 6), who had failed a median of three (2–6) therapies (BV: 50%; auto-HSCT: 17%; allogeneic HSCT: 34%), the ORR was 100% (mCR: 67%; PR: 17%; indeterminate response: 17%). Median cumulative dose for achieving best response was 160 (160–360) mg. Median PFS was 33 months. Median OS was not reached. AEs of grade 1–2 were observed in four patients, two of whom had pre-existing autoimmune conditions. Five patients with Epstein–Barr virus (EBV) positive Reed–Sternberg cells underwent monitoring of plasma EBV DNA, which became negative in four mCR patients but remained positive in one PR patient who died ultimately from refractory lymphoma. Low-dose pembrolizumab and nivolumab were highly efficacious and safe in relapsed/refractory cHL. These observations have significant financial implications in resource-constrained settings. 相似文献
10.
Pasricha SR Grigg A Catalano J Leahy M Underhill C Arthur C D'Rozario J Lowenthal R Reed K Spencer A 《Cancer》2008,113(11):3192-3198
BACKGROUND.
Administration of salvage chemotherapy to patients with relapsed or refractory lymphoma is associated with significant toxicity. Vinorelbine and gemcitabine are novel chemotherapeutic agents with minimal overlapping toxicity. We present a phase 2 study of vinorelbine and gemcitabine with or without ifosfamide administered in an ambulatory care setting for relapsed or refractory lymphoma.METHODS.
Ninety patients were enrolled. Group 1 comprised patients with “good” risk disease, Group 2 comprised patients with “high” risk disease, and Group 3 comprised patients relapsing after prior stem cell transplant. Patients in Group 1 and Group 3 received vinorelbine and gemcitabine with filgrastim support (VGF); those in Group 2 received the above regimen with ifosfamide (FGIV). We incorporated a standardized interim evaluation with dose escalation for patients with suboptimal response after 2 cycles.RESULTS.
Toxicities were acceptable. Febrile neutropenia was uncommon: 7% after VGF (7 of 107 cycles) and 19% for FGIV (26 of 148 cycles). Unplanned admissions occurred in 23 of 107 cycles (21%) after VGF and 50 of 148 (34%) after FGIV. Overall response for Groups 1, 2 and 3, respectively was 76%, 39% and 50%, with median overall survival of 28, 9 and 30 months.CONCLUSIONS.
Vinorelbine‐based and gemcitabine‐based chemotherapy is effective in the salvage setting against lymphoma and can be administered in an ambulatory setting. Cancer 2008. © 2008 American Cancer Society. 相似文献11.
Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma 总被引:3,自引:0,他引:3
Ng M Waters J Cunningham D Chau I Horwich A Hill M Norman AR Wotherspoon A Catovsky D 《British journal of cancer》2005,92(8):1352-1357
There is currently no standard salvage chemotherapy regimen in relapsed and refractory lymphoma. Gemcitabine is a novel nucleoside analogue, which acts synergistically with cisplatin both in vitro and in clinical studies. We evaluated the combination of gemcitabine, cisplatin and methylprednisolone (GEM-P) in 41 heavily pretreated patients with relapsed and refractory Hodgkin's and non-Hodgkin's lymphoma. The best-achieved response rate (RR) was 79% (95% CI 64-91), with a complete RR of 21%. In patients with chemo-resistant disease, the RR was 63%. Myelosuppression was the main toxicity, the incidence of Grade 3 or 4 anaemia, neutropenia and thrombocytopenia was 17.1, 61.0 and 53.7% respectively. Only one patient had neutropenic sepsis and none of the patients suffered from haemorrhage. Grade 3 or 4 nonhaematological toxicity was minimal and stem cell mobilisation was not inhibited. GEM-P is an effective salvage regimen and its use prior to autologous stem cell transplant warrants further investigation. 相似文献
12.
Yasuhito Terui Shinya Rai Koji Izutsu Motoko Yamaguchi Jun Takizawa Junya Kuroda Takayuki Ishikawa Koji Kato Youko Suehiro Noriko Fukuhara Ken Ohmine Hideki Goto Kazuhito Yamamoto Nobuhiro Kanemura Yasunori Ueda Kenichi Ishizawa Kyoya Kumagai Atsuko Kawasaki Tomohisa Saito Misato Hashizume Hirohiko Shibayama 《Cancer science》2021,112(7):2845-2854
Polatuzumab vedotin (pola) is a CD79b-targeted antibody-drug conjugate delivering a potent antimitotic agent (monomethyl auristatin E) to B cells. This was an open-label, single-arm study of pola 1.8 mg/kg, bendamustine 90 mg/m2, rituximab 375 mg/m2 (pola + BR) Q3W for up to six cycles in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received ≥1 prior line of therapy and were ineligible for autologous stem cell transplantation (ASCT) or experienced treatment failure with prior ASCT. Primary endpoint was complete response rate (CRR) at the end of the treatment (EOT) by positron emission tomography–computed tomography (PET-CT) using modified Lugano Response Criteria. Secondary endpoints included efficacy, safety, and pharmacokinetics. Thirty-five patients (median age 71 [range 46-86] years) were enrolled. Twenty-three (66%) patients had refractory disease, and 23 (66%) had ≥2 prior lines of therapy. At a median follow-up of 5.4 (0.7-11.9) months, patients received a median of five treatment cycles. CRR was 34.3% (95% confidence interval [CI] 19.1-52.2) at EOT. Overall response rate was 42.9% at EOT, and median progression-free survival was 5.2 months (95% CI 3.6-not evaluable). Median overall survival was not reached. No fatal adverse events (AEs) were observed. Grade 3-4 AEs were mainly hematological: anemia (37%), neutropenia (31%), white blood cell count decreased (23%), thrombocytopenia/platelet count decreased/neutrophil count decreased (20% each), and febrile neutropenia (11%). Grade 1-2 peripheral neuropathy (PN; sensory and/or motor) was reported in 14% of patients; there were no ≥grade 3 PN events. This study (JapicCTI-184048) demonstrated the efficacy and safety of pola + BR in Japanese patients with R/R DLBCL who were ineligible for ASCT. 相似文献
13.
Moskowitz C. H.; Hamlin P. A.; Gabrilove J.; Bertino J. R.; Portlock C. S.; Straus D. J.; Gencarelli A. N.; Nimer S. D.; Zelenetz A. D. 《Annals of oncology》2007,18(11):1842-1850
Introduction: HDT/ASCT is standard for relapsed and refractoryDLCL patients responding to second-line chemotherapy. We incorporateda thrombopoietic agent into the ICE chemotherapy program topotentially: decrease platelet associated toxicities, augmentstem cell collection and maintain dose intensity. Methods: This randomized, double-blind, placebo-controlled phaseI/II trial examines PEG-rHuMGDF versus placebo with ICE chemotherapy.Phase I compared three cohorts and defined a clinically effectivedose (CED). Phase II evaluated the CED versus placebo. Outcomemeasures included safety, hematological end-points, stem cellcollection and the impact of dose-intensity on outcome. Results: Forty-one patients with primary refractory (16) orrelapsed DLCL (25) were treated; Response rates for evaluablepatients are: 75% (12/16) for placebo and 82% (18/22) for PEG-rHuMGDF.PEG-rHuMGDF treated patients had significantly less grade IVthrombocytopenia, higher median platelet nadirs, and less platelettransfusion per cycle. ICE dose intensity was improved withPEG-rHuMGDF versus placebo: 75 versus 42% (P = 0.008). At 8.5years median follow-up, overall and event-free survival are47 and 31%, respectively. Patients treated on PEG-rHuMGDF versusplacebo had improved survival (59 versus 31%, P = 0.06). Conclusion: PEG-rHuMGDF ameliorated thrombocytopenia, improvedplatelet recovery, and maintained ICE dose intensity. Potentialsurvival advantages conferred by maintaining dose intensityrequire validation with newer thrombopoietic agents. Key words: dose-intensity, ICE chemotherapy, non-Hodgkin's lymphoma, refractory, relapsed, transplantation 相似文献
14.
目的:观察亚砷酸注射液(三氧化二砷,As2O3)联合吉西他滨和顺铂方案治疗难治性或复发性非霍奇金淋巴瘤(NHL)的有效率。方法:18例难治性或复发性NHL患者,男性12例,女性6例,中位年龄51岁。给予As2O3注射液10mg/d静脉滴注第1—14天,吉西他滨1000mg/m^2,第1和第8天,顺铂25mg/m^2第1—3天,21d为1个周期。结果:18例患者中完全缓解4例,部分缓解7例,有效率61.1%。肿瘤中位进展时间(TTP)6.5个月,1年生存率42.3%。不良反应主要为血液学毒性、肝肾功能损害。结论:亚砷酸注射液联合吉西他滨和顺铂方案是治疗复发或难治性非霍奇金淋巴瘤较为安全、有效的化疗方案。 相似文献
15.
Stefano Luminari MD Luigi Marcheselli MS Stefano Sacchi MD Samantha Pozzi MD Alessia Bari MD Fiorella Ilariucci MD Caterina Stelitano MD Francesco Angrilli MD Antonio Lazzaro MD Luca Baldini MD 《Cancer》2009,115(9):1906-1913
BACKGROUND:
Recent experience has suggested that there has been a stepwise improvement in the survival outcomes of patients who have follicular lymphoma with the introduction of new treatment options. In the current study, the authors report the results of 2 subsequent phase 2 trials of 238 previously untreated patients.METHODS:
In a trial of bleomycin, epidoxorubicin, cyclophosphamide, vincristine, and prednisone (BACOP) plus fludarabine, mitoxantrone, and dexamethasone (FND), 144 patients received 2 BACOP treatments followed by 4 FND treatments. In a trial of BACOP plus fludarabine and rituximab (FR), 94 patients received 3 BACOP treatments followed by 4 FR treatments.RESULTS:
The complete remission (CR) rate for BACOP/FND was 62%. After a median follow‐up of 60 months, the failure‐free survival (FFS) and overall survival (OS) rates at 4 years were 53% and 77%, respectively. The CR rate for BACOP/FR was 79%. After a median follow‐up of 36 months, the FFS and OS rates at 4 years were 56% and 97%, respectively, which were significant compared with the CR and OS rates achieved with BACOP/FND. Twenty‐five of 42 bcl‐2‐positive patients attained a molecularly negative CR and had improved FFS. No significant differences were observed between the 2 trials in the percentage of infections or neutropenia.CONCLUSIONS:
The CR and OS rates achieved with BACOP/FR were better, and overall toxicity did not increase. Furthermore, patients who received rituximab had a better FFS compared with patients who received chemotherapy alone. Finally, although conclusions between nonrandomized groups may depend on differences in observed and unobserved prognostic features, the current results suggested that the addition of rituximab to anthracycline‐fludarabine–containing regimens have a favorable effect on the prognosis of patients with advanced follicular lymphoma. Cancer 2009. © 2009 American Cancer Society. 相似文献16.
Kang HJ Lee SS Kim KM Choi TH Cheon GJ Kim WS Suh C Yang SH Lim SM 《Asia-Pacific Journal of Clinical Oncology》2011,7(2):136-145
Aim: To evaluate the efficacy and safety of radioimmunotherapy (RIT) with radioiodinated human/murine chimeric anti‐CD20 monoclonal antibody rituximab (131I‐rituximab) for treating Korean patients with relapsed or refractory B‐cell non‐Hodgkin's lymphomas (NHL). Methods: All patients received unlabeled rituximab 70 mg immediately prior to the administration of a therapeutic dose (median dose: 7.3 GBq) of 131I‐rituximab. The tumor response was evaluated 1 month later by contrast enhanced 18F‐fludeoxyglucose positron emission tomography‐computed tomography. Results: Between May 2004 and October 2006, 24 patients received single treatment with 131I‐rituximab. The overall response rate (ORR) was 29%; 46% (three complete responses, two partial responses (PR) for patients with low grade B‐cell NHL (LGL) and 9% (one PR) for patients with diffuse large B‐cell lymphoma (DLBCL). After a median follow‐up of 55 months, the median progression‐free survival (PFS) for all the patients was 2.2 months. The median overall survival (OS) was 11.3 months. There were statistically significant differences between the LGL and the DLBCL for the median PFS (4.5 months vs 1.3 months, respectively, P = 0.0007) and the median OS (30.3 months vs 6.5 months, respectively, P = 0.0295). Grades 3–4 thrombocytopenia and neutropenia occurred in 33% (8/24) and 21% (5/24) of the patients, respectively. Conclusion: RIT with 131I‐rituximab seems to be effective and tolerable for patients with refractory LGL, although this treatment had modest activity in patients with refractory DLBCL. Further studies are warranted to determine the efficacy of 131I‐rituximab for treating the patients with DLBCL. 相似文献
17.
目的:观察反应停联合DICE方案治疗难治性复发型非霍奇金淋巴瘤(NHL)的临床疗效及不良反应.方法:将64例难治性/复发型NHL患者随机分为两组,对照组采用DICE方案治疗,治疗组采用反应停联合DICE方案治疗,以21d为1个周期,对完成4个周期以上者进行疗效评价随访1年和2年生存率.结果:治疗组32例中完全缓解(CR)l5例(46.88%),部分缓解(PR)8例(25.00%),总有效率71.88%;对照组32例中CR 8例(25.00%),PR 6例(18.75%),总有效率为46.88%,两组比较有显著性差异.治疗组1年生存率和2年生存率分别为81.25% (26/32)和56.25% (18/32 ),对照组1年生存率和2年生存率分别为 75.0% (24/32)和40.62%(13/32),较之对照组,治疗组1年生存率有增加趋势,但统计学比较无差异,而2年生存率两组比较有统计学差异(P<0.05).结论:反应停联合DICE方案治疗难治性复发型NHL疗效满意,不良反应可以耐受,值得进一步研究应用. 相似文献
18.
Dose,schedule, safety,and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
下载免费PDF全文
![点击此处可从《Cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Gail J. Roboz MD Hagop M. Kantarjian MD Karen W. L. Yee MD Patricia L. Kropf MD Casey L. O'Connell MD Elizabeth A. Griffiths MD Wendy Stock MD Naval G. Daver MD Elias Jabbour MD Ellen K. Ritchie MD Katherine J. Walsh MD David Rizzieri MD Scott D. Lunin MD Tania Curio MD Woonbok Chung PhD Yong Hao MD James N. Lowder MD Mohammad Azab MD Jean‐Pierre J. Issa MD 《Cancer》2018,124(2):325-334
19.
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan 总被引:3,自引:0,他引:3
Witzig TE Molina A Gordon LI Emmanouilides C Schilder RJ Flinn IW Darif M Macklis R Vo K Wiseman GA 《Cancer》2007,109(9):1804-1810
BACKGROUND: Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. METHODS: Data on patients with recurring NHL treated with yttrium Y 90 ibritumomab tiuxetan in 4 clinical trials were reviewed to identify patients with a long-term response, defined as a time to progression of 12 months or longer. RESULTS: Long-term responses were seen in 37% (78/211) of patients. At a median follow-up of 53.5 months (range, 12.7-88.9) the median duration of response was 28.1 months and the median time to progression was 29.3 months. A third of these patients had been treated with at least 3 previous therapies, and 37% of them had not responded to their last therapy. The findings in patients with follicular lymphoma (n=59) were similar to those in the overall population of long-term responders. The estimated overall survival at 5 years was 53% for all patients treated with 90Y ibritumomab tiuxetan and 81% for long-term responders. CONCLUSIONS: A single dose of 90Y ibritumomab tiuxetan can produce durable responses and prolonged overall survival in a substantial number of patients in whom previous therapies have failed. 相似文献
20.
A phase 2 study of methotrexate,etoposide, dexamethasone,and pegaspargase chemotherapy for newly diagnosed,relapsed, or refractory extranodal natural killer/T‐cell lymphoma,nasal type: a multicenter trial in Northwest China
下载免费PDF全文
![点击此处可从《Hematological oncology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Rong Liang Guang‐xun Gao Jie‐ping Chen Ji‐shi Wang Xiao‐min Wang Yun Zeng Qing‐xian Bai Tao Zhang Lan Yang Bao‐xia Dong Hong‐tao Gu Mi‐mi Shu Cai‐xia Hao Jian‐hong Wang Na Zhang Xie‐qun Chen 《Hematological oncology》2017,35(4):619-629
The nasal type of extranodal natural killer/T‐cell lymphoma is a rare aggressive lymphoma with poor prognosis. To discover a successful treatment, we investigated the efficacy and safety of chemotherapy with methotrexate, etoposide, dexamethasone, and polyethylene glycol‐asparaginase (MESA). Three cycles of MESA were administered to 46 patients with new or relapsed/refractory natural killer/T‐cell lymphoma. Complete response after 3 treatment cycles was 43.5%, the overall response rate was 87%, and 2‐year overall survival was 83.4%. Complete response was significantly better for newly diagnosed patients than for patients with relapsed/refractory disease. Patients with newly diagnosed disease had a significantly better overall response rate after 1, but not after 2 or 3 treatment cycles. Overall survival and progression‐free survival did not differ over 2 years. Grade 1/2 toxicities were frequent, but MESA was associated with fewer grade 3/4 events or treatment‐related deaths. These results will require confirmation in larger prospective trials. 相似文献